Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
03 12월 2021 - 6:15AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16
or 15d-16
Under the Securities Exchange Act of 1934
For the Month of November 2021
Commission File Number: 001-37353
BIONDVAX PHARMACEUTICALS LTD.
(Translation of registrant’s name into English)
Jerusalem BioPark, 2nd Floor
Hadassah Ein Kerem Campus
Jerusalem, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
On November
30, 2021, BiondVax Pharmaceuticals Ltd. issued a press release announcing third quarter 2021 financial results.
Exhibit Index
This Report
on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (Registration No.
333-240189) and its Registration Statement on Form S-8 (Registration No. 333-239344).
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
BiondVax Pharmaceuticals Ltd.
|
|
|
|
Date: December 2, 2021
|
By:
|
/s/ Amir Reichman
|
|
|
Amir Reichman
|
|
|
Chief Executive Officer
|
Biovaxys Technology (QB) (USOTC:BVAXF)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Biovaxys Technology (QB) (USOTC:BVAXF)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
Biovaxys Technology Corporation (QB) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More Biondvax Pharmaceuticals Ltd. News Articles